George Daley

Publications

1. Protocol for the generation of HLF+ HOXA+ human hematopoietic progenitor cells from pluripotent stem cells. STAR Protoc. 2025 Jan 24; 6(1):103592. View Abstract
2. Maturation and persistence of CAR T cells derived from human pluripotent stem cells via chemical inhibition of G9a/GLP. Cell Stem Cell. 2025 Jan 15. View Abstract
3. The dynamics of hematopoiesis over the human lifespan. Nat Methods. 2024 Dec 05. View Abstract
4. Maturation and persistence of CAR T cells derived from human pluripotent stem cells via chemical inhibition of G9a/GLP. Cell Stem Cell. 2025 Jan 02; 32(1):71-85.e5. View Abstract
5. Bnip3lb-driven mitophagy sustains expansion of the embryonic hematopoietic stem cell pool. bioRxiv. 2024 Sep 23. View Abstract
6. Liver cancer initiation requires translational activation by an oncofetal regulon involving LIN28 proteins. J Clin Invest. 2024 Jun 13; 134(15). View Abstract
7. Hematopoietic stem cell division is governed by distinct RUNX1 binding partners. bioRxiv. 2024 Jun 08. View Abstract
8. Welcoming the Era of Gene Editing in Medicine. N Engl J Med. 2024 May 09; 390(18):1642-1645. View Abstract
9. Dynamic nucleolar phase separation influenced by non-canonical function of LIN28A instructs pluripotent stem cell fate decisions. Nat Commun. 2024 Feb 10; 15(1):1256. View Abstract
10. Regenerative Medicine: Case Study for Understanding and Anticipating Emerging Science and Technology. NAM Perspect. 2023; 2023. View Abstract
11. Development of functional resident macrophages in human pluripotent stem cell-derived colonic organoids and human fetal colon. Cell Stem Cell. 2023 11 02; 30(11):1434-1451.e9. View Abstract
12. Extracellular vesicles improve GABAergic transmission in Huntington's disease iPSC-derived neurons. Theranostics. 2023; 13(11):3707-3724. View Abstract
13. Raman microspectroscopy reveals unsaturation heterogeneity at the lipid droplet level and validates an in vitro model of bone marrow adipocyte subtypes. Front Endocrinol (Lausanne). 2022; 13:1001210. View Abstract
14. EZH1 repression generates mature iPSC-derived CAR T cells with enhanced antitumor activity. Cell Stem Cell. 2022 08 04; 29(8):1181-1196.e6. View Abstract
15. Lifelong multilineage contribution by embryonic-born blood progenitors. Nature. 2022 06; 606(7915):747-753. View Abstract
16. Anniversary reflections: ISSCR presidents on 20 years of progress. Cell Stem Cell. 2022 06 02; 29(6):876-878. View Abstract
17. Hypoxic, glycolytic metabolism is a vulnerability of B-acute lymphoblastic leukemia-initiating cells. Cell Rep. 2022 04 26; 39(4):110752. View Abstract
18. CellComm infers cellular crosstalk that drives haematopoietic stem and progenitor cell development. Nat Cell Biol. 2022 04; 24(4):579-589. View Abstract
19. Developmental maturation of the hematopoietic system controlled by a Lin28b-let-7-Cbx2 axis. Cell Rep. 2022 04 05; 39(1):110587. View Abstract
20. Dipping a toe in the fountain of youth. Nat Aging. 2022 03; 2(3):192-194. View Abstract
21. Allelic variation in class I HLA determines CD8+ T cell repertoire shape and cross-reactive memory responses to SARS-CoV-2. Sci Immunol. 2022 01 21; 7(67):eabk3070. View Abstract
22. LIN28B alters ribosomal dynamics to promote metastasis in MYCN-driven malignancy. J Clin Invest. 2021 11 15; 131(22). View Abstract
23. rRNA biogenesis regulates mouse 2C-like state by 3D structure reorganization of peri-nucleolar heterochromatin. Nat Commun. 2021 11 09; 12(1):6365. View Abstract
24. Oncogenic switch and single-agent MET inhibitor sensitivity in a subset of EGFR-mutant lung cancer. Sci Transl Med. 2021 Sep; 13(609):eabb3738. View Abstract
25. LIN28 coordinately promotes nucleolar/ribosomal functions and represses the 2C-like transcriptional program in pluripotent stem cells. Protein Cell. 2022 07; 13(7):490-512. View Abstract
26. Evidence generation and reproducibility in cell and gene therapy research: A call to action. Mol Ther Methods Clin Dev. 2021 Sep 10; 22:11-14. View Abstract
27. Lin28 paralogs regulate lung branching morphogenesis. Cell Rep. 2021 07 20; 36(3):109408. View Abstract
28. Sequential regulation of hemogenic fate and hematopoietic stem and progenitor cell formation from arterial endothelium by Ezh1/2. Stem Cell Reports. 2021 07 13; 16(7):1718-1734. View Abstract
29. ISSCR Guidelines for Stem Cell Research and Clinical Translation: The 2021 update. Stem Cell Reports. 2021 06 08; 16(6):1398-1408. View Abstract
30. Calmodulin inhibitors improve erythropoiesis in Diamond-Blackfan anemia. Sci Transl Med. 2020 10 21; 12(566). View Abstract
31. An induced pluripotent stem cell model of Fanconi anemia reveals mechanisms of p53-driven progenitor cell differentiation. Blood Adv. 2020 10 13; 4(19):4679-4692. View Abstract
32. Mitochondrial and Redox Modifications in Huntington Disease Induced Pluripotent Stem Cells Rescued by CRISPR/Cas9 CAGs Targeting. Front Cell Dev Biol. 2020; 8:576592. View Abstract
33. Diversification of reprogramming trajectories revealed by parallel single-cell transcriptome and chromatin accessibility sequencing. Sci Adv. 2020 09; 6(37). View Abstract
34. Metabolic Regulation of Inflammasome Activity Controls Embryonic Hematopoietic Stem and Progenitor Cell Production. Dev Cell. 2020 10 26; 55(2):133-149.e6. View Abstract
35. Pancreatic circulating tumor cell profiling identifies LIN28B as a metastasis driver and drug target. Nat Commun. 2020 07 03; 11(1):3303. View Abstract
36. LIN28B regulates transcription and potentiates MYCN-induced neuroblastoma through binding to ZNF143 at target gene promotors. Proc Natl Acad Sci U S A. 2020 07 14; 117(28):16516-16526. View Abstract
37. COVID Highlights Another Crisis: Lack of Black Physicians and Scientists. Med. 2021 01 15; 2(1):2-3. View Abstract
38. Oral health care in the 21st century: It is time for the integration of dental and medical education. J Dent Educ. 2020 Sep; 84(9):999-1002. View Abstract
39. Transcriptome Dynamics of Hematopoietic Stem Cell Formation Revealed Using a Combinatorial Runx1 and Ly6a Reporter System. Stem Cell Reports. 2020 05 12; 14(5):956-971. View Abstract
40. The Toughest Triage - Allocating Ventilators in a Pandemic. N Engl J Med. 2020 May 21; 382(21):1973-1975. View Abstract
41. Author Correction: Lin28 and let-7 regulate the timing of cessation of murine nephrogenesis. Nat Commun. 2020 Mar 09; 11(1):1327. View Abstract
42. A nanobody targeting the LIN28:let-7 interaction fragment of TUT4 blocks uridylation of let-7. Proc Natl Acad Sci U S A. 2020 03 03; 117(9):4653-4663. View Abstract
43. YAP Regulates Hematopoietic Stem Cell Formation in Response to the Biomechanical Forces of Blood Flow. Dev Cell. 2020 02 24; 52(4):446-460.e5. View Abstract
44. Introduction to the Special Issue on CRISPR. Perspect Biol Med. 2020; 63(1):1-13. View Abstract
45. Author Correction: Epoxyeicosatrienoic acids enhance embryonic haematopoiesis and adult marrow engraftment. Nature. 2019 Sep; 573(7772):E1. View Abstract
46. Author Correction: A systems biology pipeline identifies regulatory networks for stem cell engineering. Nat Biotechnol. 2019 Aug; 37(8):962. View Abstract
47. A systems biology pipeline identifies regulatory networks for stem cell engineering. Nat Biotechnol. 2019 07; 37(7):810-818. View Abstract
48. Induced pluripotent stem cells in disease modelling and drug discovery. Nat Rev Genet. 2019 07; 20(7):377-388. View Abstract
49. Stem Cells in the Treatment of Disease. N Engl J Med. 2019 05 02; 380(18):1748-1760. View Abstract
50. Retraction Note: NF-?B activation impairs somatic cell reprogramming in ageing. Nat Cell Biol. 2019 Mar; 21(3):410. View Abstract
51. The developmental stage of the hematopoietic niche regulates lineage in MLL-rearranged leukemia. J Exp Med. 2019 03 04; 216(3):527-538. View Abstract
52. The Lin28/let-7 Pathway Regulates the Mammalian Caudal Body Axis Elongation Program. Dev Cell. 2019 02 11; 48(3):396-405.e3. View Abstract
53. After the Storm - A Responsible Path for Genome Editing. N Engl J Med. 2019 Mar 07; 380(10):897-899. View Abstract
54. Lin28 and let-7 regulate the timing of cessation of murine nephrogenesis. Nat Commun. 2019 01 11; 10(1):168. View Abstract
55. Lin28b regulates age-dependent differences in murine platelet function. Blood Adv. 2019 01 08; 3(1):72-82. View Abstract
56. Building Capacity for a Global Genome Editing Observatory: Institutional Design. Trends Biotechnol. 2018 08; 36(8):741-743. View Abstract
57. Small-Molecule Inhibitors Disrupt let-7 Oligouridylation and Release the Selective Blockade of let-7 Processing by LIN28. Cell Rep. 2018 06 05; 23(10):3091-3101. View Abstract
58. Building Capacity for a Global Genome Editing Observatory: Conceptual Challenges. Trends Biotechnol. 2018 07; 36(7):639-641. View Abstract
59. A CLK3-HMGA2 Alternative Splicing Axis Impacts Human Hematopoietic Stem Cell Molecular Identity throughout Development. Cell Stem Cell. 2018 04 05; 22(4):575-588.e7. View Abstract
60. Reconstruction of complex single-cell trajectories using CellRouter. Nat Commun. 2018 03 01; 9(1):892. View Abstract
61. Regulation of embryonic haematopoietic multipotency by EZH1. Nature. 2018 01 25; 553(7689):506-510. View Abstract
62. Comprehensive Mapping of Pluripotent Stem Cell Metabolism Using Dynamic Genome-Scale Network Modeling. Cell Rep. 2017 Dec 05; 21(10):2965-2977. View Abstract
63. Is There Merit in Merit Aid? N Engl J Med. 2017 Dec 21; 377(25):2415-2417. View Abstract
64. Using CRISPR-Cas9 to Generate Gene-Corrected Autologous iPSCs for the Treatment of Inherited Retinal Degeneration. Mol Ther. 2017 Sep 06; 25(9):1999-2013. View Abstract
65. Haematopoietic stem and progenitor cells from human pluripotent stem cells. Nature. 2017 05 25; 545(7655):432-438. View Abstract
66. Reassembling embryos in vitro from component stem cells. Cell Res. 2017 Aug; 27(8):961-962. View Abstract
67. Autophagy: It's in Your Blood. Dev Cell. 2017 03 27; 40(6):518-520. View Abstract
68. Polar Extremes in the Clinical Use of Stem Cells. N Engl J Med. 2017 03 16; 376(11):1075-1077. View Abstract
69. Signaling through RNA-binding proteins as a cell fate regulatory mechanism. Cell Cycle. 2017 04 18; 16(8):723-724. View Abstract
70. Drug discovery for Diamond-Blackfan anemia using reprogrammed hematopoietic progenitors. Sci Transl Med. 2017 02 08; 9(376). View Abstract
71. Disruptive reproductive technologies. Sci Transl Med. 2017 01 11; 9(372). View Abstract
72. Engineered Murine HSCs Reconstitute Multi-lineage Hematopoiesis and Adaptive Immunity. Cell Rep. 2016 12 20; 17(12):3178-3192. View Abstract
73. LIN28 phosphorylation by MAPK/ERK couples signalling to the post-transcriptional control of pluripotency. Nat Cell Biol. 2017 Jan; 19(1):60-67. View Abstract
74. Stem cells: Valine starvation leads to a hungry niche. Nature. 2017 01 12; 541(7636):166-167. View Abstract
75. The LIN28B/let-7 axis is a novel therapeutic pathway in multiple myeloma. Leukemia. 2017 04; 31(4):853-860. View Abstract
76. TGF-ß inhibitors stimulate red blood cell production by enhancing self-renewal of BFU-E erythroid progenitors. Blood. 2016 12 08; 128(23):2637-2641. View Abstract
77. Progress towards generation of human haematopoietic stem cells. Nat Cell Biol. 2016 Nov; 18(11):1111-1117. View Abstract
78. Developmental Vitamin D Availability Impacts Hematopoietic Stem Cell Production. Cell Rep. 2016 10 04; 17(2):458-468. View Abstract
79. Developmental regulation of myeloerythroid progenitor function by the Lin28b-let-7-Hmga2 axis. J Exp Med. 2016 07 25; 213(8):1497-512. View Abstract
80. Multiple mechanisms disrupt the let-7 microRNA family in neuroblastoma. Nature. 2016 07 14; 535(7611):246-51. View Abstract
81. LIN28 Regulates Stem Cell Metabolism and Conversion to Primed Pluripotency. Cell Stem Cell. 2016 07 07; 19(1):66-80. View Abstract
82. RNAi Reveals Phase-Specific Global Regulators of Human Somatic Cell Reprogramming. Cell Rep. 2016 06 21; 15(12):2597-607. View Abstract
83. Engineering Hematopoietic Stem Cells: Lessons from Development. Cell Stem Cell. 2016 06 02; 18(6):707-720. View Abstract
84. Policy: Global standards for stem-cell research. Nature. 2016 05 19; 533(7603):311-3. View Abstract
85. New ISSCR guidelines: clinical translation of stem cell research. Lancet. 2016 May 14; 387(10032):1979-81. View Abstract
86. SCIENTIFIC COMMUNITY. Confronting stem cell hype. Science. 2016 May 13; 352(6287):776-7. View Abstract
87. Setting Global Standards for Stem Cell Research and Clinical Translation: The 2016 ISSCR Guidelines. Stem Cell Reports. 2016 06 14; 6(6):787-797. View Abstract
88. Chronic myeloid leukemia: reminiscences and dreams. Haematologica. 2016 05; 101(5):541-58. View Abstract
89. Interferon-a signaling promotes embryonic HSC maturation. Blood. 2016 07 14; 128(2):204-16. View Abstract
90. Sex-specific regulation of weight and puberty by the Lin28/let-7 axis. J Endocrinol. 2016 Mar; 228(3):179-91. View Abstract
91. Corrigendum: Failure to replicate the STAP cell phenomenon. Nature. 2016 Mar 17; 531(7594):400. View Abstract
92. Corrigendum: Hallmarks of pluripotency. Nature. 2016 Mar 17; 531(7594):400. View Abstract
93. Stem cells and the evolving notion of cellular identity. Philos Trans R Soc Lond B Biol Sci. 2015 Oct 19; 370(1680):20140376. View Abstract
94. Precise let-7 expression levels balance organ regeneration against tumor suppression. Elife. 2015 Oct 07; 4:e09431. View Abstract
95. Failure to replicate the STAP cell phenomenon. Nature. 2015 Sep 24; 525(7570):E6-9. View Abstract
96. Hallmarks of pluripotency. Nature. 2015 Sep 24; 525(7570):469-78. View Abstract
97. Hematopoietic stem cells develop in the absence of endothelial cadherin 5 expression. Blood. 2015 Dec 24; 126(26):2811-20. View Abstract
98. Systematic identification of factors for provirus silencing in embryonic stem cells. Cell. 2015 Sep 24; 163(1):230-45. View Abstract
99. PRC2 Is Required to Maintain Expression of the Maternal Gtl2-Rian-Mirg Locus by Preventing De Novo DNA Methylation in Mouse Embryonic Stem Cells. Cell Rep. 2015 Sep 01; 12(9):1456-70. View Abstract
100. NF-?B activation impairs somatic cell reprogramming in ageing. Nat Cell Biol. 2015 Aug; 17(8):1004-13. View Abstract
101. Epoxyeicosatrienoic acids enhance embryonic haematopoiesis and adult marrow engraftment. Nature. 2015 Jul 23; 523(7561):468-71. View Abstract
102. In Support of a Patient-Driven Initiative and Petition to Lower the High Price of Cancer Drugs. Mayo Clin Proc. 2015 Aug; 90(8):996-1000. View Abstract
103. Integrative Analyses of Human Reprogramming Reveal Dynamic Nature of Induced Pluripotency. Cell. 2015 Jul 16; 162(2):412-424. View Abstract
104. Two new routes to make blood: Hematopoietic specification from pluripotent cell lines versus reprogramming of somatic cells. Exp Hematol. 2015 Sep; 43(9):756-9. View Abstract
105. Transplantation of Macaca cynomolgus iPS-derived hematopoietic cells in NSG immunodeficient mice. Haematologica. 2015 Oct; 100(10):e428-31. View Abstract
106. LIN28 cooperates with WNT signaling to drive invasive intestinal and colorectal adenocarcinoma in mice and humans. Genes Dev. 2015 May 15; 29(10):1074-86. View Abstract
107. Correction: Transplantation of Adult Mouse iPS Cell-Derived Photoreceptor Precursors Restores Retinal Structure and Function in Degenerative Mice. PLoS One. 2015; 10(5):e0125947. View Abstract
108. Biomechanical forces promote blood development through prostaglandin E2 and the cAMP-PKA signaling axis. J Exp Med. 2015 May 04; 212(5):665-80. View Abstract
109. Adenosine signaling promotes hematopoietic stem and progenitor cell emergence. J Exp Med. 2015 May 04; 212(5):649-63. View Abstract
110. Flow-induced protein kinase A-CREB pathway acts via BMP signaling to promote HSC emergence. J Exp Med. 2015 May 04; 212(5):633-48. View Abstract
111. Biotechnology. A prudent path forward for genomic engineering and germline gene modification. Science. 2015 Apr 03; 348(6230):36-8. View Abstract
112. De novo generation of HSCs from somatic and pluripotent stem cell sources. Blood. 2015 Apr 23; 125(17):2641-8. View Abstract
113. Metabolic switches linked to pluripotency and embryonic stem cell differentiation. Cell Metab. 2015 Mar 03; 21(3):349-50. View Abstract
114. The role of Lin28b in myeloid and mast cell differentiation and mast cell malignancy. Leukemia. 2015 Jun; 29(6):1320-30. View Abstract
115. Notch1 acts via Foxc2 to promote definitive hematopoiesis via effects on hemogenic endothelium. Blood. 2015 Feb 26; 125(9):1418-26. View Abstract
116. Dissecting reprogramming, differentiation and conversion with network biology. Leuk Suppl. 2014 Dec; 3(Suppl 1):S3-4. View Abstract
117. Deconstructing transcriptional heterogeneity in pluripotent stem cells. Nature. 2014 Dec 04; 516(7529):56-61. View Abstract
118. A comparison of non-integrating reprogramming methods. Nat Biotechnol. 2015 Jan; 33(1):58-63. View Abstract
119. A nontranscriptional role for Oct4 in the regulation of mitotic entry. Proc Natl Acad Sci U S A. 2014 Nov 04; 111(44):15768-73. View Abstract
120. Deriving blood stem cells from pluripotent stem cells for research and therapy. Best Pract Res Clin Haematol. 2014 Sep-Dec; 27(3-4):293-7. View Abstract
121. The epithelial-mesenchymal transition factor SNAIL paradoxically enhances reprogramming. Stem Cell Reports. 2014 Nov 11; 3(5):691-8. View Abstract
122. Stem cell therapy. Use of differentiated pluripotent stem cells as replacement therapy for treating disease. Science. 2014 Aug 22; 345(6199):1247391. View Abstract
123. CellNet: network biology applied to stem cell engineering. Cell. 2014 Aug 14; 158(4):903-915. View Abstract
124. Dissecting engineered cell types and enhancing cell fate conversion via CellNet. Cell. 2014 Aug 14; 158(4):889-902. View Abstract
125. Lin28b is sufficient to drive liver cancer and necessary for its maintenance in murine models. Cancer Cell. 2014 Aug 11; 26(2):248-61. View Abstract
126. Effect of developmental stage of HSC and recipient on transplant outcomes. Dev Cell. 2014 Jun 09; 29(5):621-628. View Abstract
127. Alternative splicing of MBD2 supports self-renewal in human pluripotent stem cells. Cell Stem Cell. 2014 Jul 03; 15(1):92-101. View Abstract
128. Functional evaluation of ES-somatic cell hybrids in vitro and in vivo. Cell Reprogram. 2014 Jun; 16(3):167-74. View Abstract
129. Lin28 sustains early renal progenitors and induces Wilms tumor. Genes Dev. 2014 May 01; 28(9):971-82. View Abstract
130. Musashi-2 controls cell fate, lineage bias, and TGF-ß signaling in HSCs. J Exp Med. 2014 Jan 13; 211(1):71-87. View Abstract
131. Defining cellular identity through network biology. Cell Cycle. 2014; 13(21):3313-4. View Abstract
132. Distinct and combinatorial functions of Jmjd2b/Kdm4b and Jmjd2c/Kdm4c in mouse embryonic stem cell identity. Mol Cell. 2014 01 09; 53(1):32-48. View Abstract
133. Development. A stem cell perspective on cellular engineering. Science. 2013 Nov 08; 342(6159):700-2. View Abstract
134. Lin28 enhances tissue repair by reprogramming cellular metabolism. Cell. 2013 Nov 07; 155(4):778-92. View Abstract
135. Human endogenous retrovirus K (HML-2) RNA and protein expression is a marker for human embryonic and induced pluripotent stem cells. Retrovirology. 2013 Oct 24; 10:115. View Abstract
136. Proteolytic autodigestion: common tissue pathology in Shwachman-Diamond syndrome? Cell Cycle. 2013; 12(22):3457-8. View Abstract
137. Induction of multipotential hematopoietic progenitors from human pluripotent stem cells via respecification of lineage-restricted precursors. Cell Stem Cell. 2013 Oct 03; 13(4):459-70. View Abstract
138. Hematopoietic defects and iPSC disease modeling: lessons learned. Immunol Lett. 2013 Sep-Oct; 155(1-2):18-20. View Abstract
139. Stem cells: Reprogramming in situ. Nature. 2013 Oct 17; 502(7471):309-10. View Abstract
140. A chemical logic for reprogramming to pluripotency. Cell Res. 2013 Dec; 23(12):1337-8. View Abstract
141. Fetal deficiency of lin28 programs life-long aberrations in growth and glucose metabolism. Stem Cells. 2013 Aug; 31(8):1563-73. View Abstract
142. Optimization of scarless human stem cell genome editing. Nucleic Acids Res. 2013 Oct; 41(19):9049-61. View Abstract
143. Induced pluripotent stem cells with a mitochondrial DNA deletion. Stem Cells. 2013 Jul; 31(7):1287-97. View Abstract
144. A new route to human embryonic stem cells. Nat Med. 2013 Jul; 19(7):820-1. View Abstract
145. Comment on "Drug screening for ALS using patient-specific induced pluripotent stem cells". Sci Transl Med. 2013 Jun 05; 5(188):188le2. View Abstract
146. Notch-HES1 signaling axis controls hemato-endothelial fate decisions of human embryonic and induced pluripotent stem cells. Blood. 2013 Aug 15; 122(7):1162-73. View Abstract
147. Stem cell metabolism in tissue development and aging. Development. 2013 Jun; 140(12):2535-47. View Abstract
148. Origins and implications of pluripotent stem cell variability and heterogeneity. Nat Rev Mol Cell Biol. 2013 Jun; 14(6):357-68. View Abstract
149. Regulation of stem cell therapies under attack in Europe: for whom the bell tolls. EMBO J. 2013 May 29; 32(11):1489-95. View Abstract
150. Lin28a regulates germ cell pool size and fertility. Stem Cells. 2013 May; 31(5):1001-9. View Abstract
151. Deciphering the rules of ceRNA networks. Proc Natl Acad Sci U S A. 2013 Apr 30; 110(18):7112-3. View Abstract
152. Pluripotent stem cell models of Shwachman-Diamond syndrome reveal a common mechanism for pancreatic and hematopoietic dysfunction. Cell Stem Cell. 2013 Jun 06; 12(6):727-36. View Abstract
153. Lin28: primal regulator of growth and metabolism in stem cells. Cell Stem Cell. 2013 Apr 04; 12(4):395-406. View Abstract
154. The Src homology 2 protein Shb promotes cell cycle progression in murine hematopoietic stem cells by regulation of focal adhesion kinase activity. Exp Cell Res. 2013 Jul 15; 319(12):1852-1864. View Abstract
155. A blueprint for engineering cell fate: current technologies to reprogram cell identity. Cell Res. 2013 Jan; 23(1):33-48. View Abstract
156. Reprogrammed cells for disease modeling and regenerative medicine. Annu Rev Med. 2013; 64:277-90. View Abstract
157. Signaling axis involving Hedgehog, Notch, and Scl promotes the embryonic endothelial-to-hematopoietic transition. Proc Natl Acad Sci U S A. 2013 Jan 08; 110(2):E141-50. View Abstract
158. Cellular alchemy and the golden age of reprogramming. Cell. 2012 Dec 07; 151(6):1151-4. View Abstract
159. Zcchc11 uridylates mature miRNAs to enhance neonatal IGF-1 expression, growth, and survival. PLoS Genet. 2012; 8(11):e1003105. View Abstract
160. Metabolic regulation in pluripotent stem cells during reprogramming and self-renewal. Cell Stem Cell. 2012 Nov 02; 11(5):589-95. View Abstract
161. The transcriptional landscape of hematopoietic stem cell ontogeny. Cell Stem Cell. 2012 Nov 02; 11(5):701-14. View Abstract
162. Influence of threonine metabolism on S-adenosylmethionine and histone methylation. Science. 2013 Jan 11; 339(6116):222-6. View Abstract
163. Impaired intrinsic immunity to HSV-1 in human iPSC-derived TLR3-deficient CNS cells. Nature. 2012 Nov 29; 491(7426):769-73. View Abstract
164. Euchromatin islands in large heterochromatin domains are enriched for CTCF binding and differentially DNA-methylated regions. BMC Genomics. 2012 Oct 26; 13:566. View Abstract
165. Altered hematopoiesis in trisomy 21 as revealed through in vitro differentiation of isogenic human pluripotent cells. Proc Natl Acad Sci U S A. 2012 Oct 23; 109(43):17567-72. View Abstract
166. Therapeutic potential of human induced pluripotent stem cells in experimental stroke. Cell Transplant. 2013; 22(8):1427-40. View Abstract
167. Quantitative proteomic analysis of induced pluripotent stem cells derived from a human Huntington's disease patient. Biochem J. 2012 Sep 15; 446(3):359-71. View Abstract
168. Neuronal properties, in vivo effects, and pathology of a Huntington's disease patient-derived induced pluripotent stem cells. Stem Cells. 2012 Sep; 30(9):2054-62. View Abstract
169. Functional vascular smooth muscle cells derived from human induced pluripotent stem cells via mesenchymal stem cell intermediates. Cardiovasc Res. 2012 Dec 01; 96(3):391-400. View Abstract
170. Caudal genes in blood development and leukemia. Ann N Y Acad Sci. 2012 Aug; 1266:47-54. View Abstract
171. New lessons learned from disease modeling with induced pluripotent stem cells. Curr Opin Genet Dev. 2012 Oct; 22(5):500-8. View Abstract
172. The promise and perils of stem cell therapeutics. Cell Stem Cell. 2012 Jun 14; 10(6):740-749. View Abstract
173. Stem cells assessed. Nat Rev Mol Cell Biol. 2012 06 08; 13(7):471-6. View Abstract
174. Pluripotent stem cells in research and treatment of hemoglobinopathies. Cold Spring Harb Perspect Med. 2012 Apr; 2(4):a011841. View Abstract
175. Accessing naïve human pluripotency. Curr Opin Genet Dev. 2012 Jun; 22(3):272-82. View Abstract
176. Mutant induced pluripotent stem cell lines recapitulate aspects of TDP-43 proteinopathies and reveal cell-specific vulnerability. Proc Natl Acad Sci U S A. 2012 Apr 10; 109(15):5803-8. View Abstract
177. Reprogramming cellular identity for regenerative medicine. Cell. 2012 Mar 16; 148(6):1110-22. View Abstract
178. Nanog-like regulates endoderm formation through the Mxtx2-Nodal pathway. Dev Cell. 2012 Mar 13; 22(3):625-38. View Abstract
179. Chromatin-modifying enzymes as modulators of reprogramming. Nature. 2012 Mar 04; 483(7391):598-602. View Abstract
180. Overcoming reprogramming resistance of Fanconi anemia cells. Blood. 2012 Jun 07; 119(23):5449-57. View Abstract
181. The promise of induced pluripotent stem cells in research and therapy. Nature. 2012 Jan 18; 481(7381):295-305. View Abstract
182. Derivation of human embryonic stem cells with NEMO deficiency. Stem Cell Res. 2012 May; 8(3):410-5. View Abstract
183. Excision of a viral reprogramming cassette by delivery of synthetic Cre mRNA. Curr Protoc Stem Cell Biol. 2012; Chapter 4:Unit4A.5. View Abstract
184. Polycomb repressive complex 2 regulates normal development of the mouse heart. Circ Res. 2012 Feb 03; 110(3):406-15. View Abstract
185. Live-cell immunofluorescence staining of human pluripotent stem cells. Curr Protoc Stem Cell Biol. 2011 Dec; Chapter 1:Unit 1C.12. View Abstract
186. Donor cell type can influence the epigenome and differentiation potential of human induced pluripotent stem cells. Nat Biotechnol. 2011 Nov 27; 29(12):1117-9. View Abstract
187. Screening ethnically diverse human embryonic stem cells identifies a chromosome 20 minimal amplicon conferring growth advantage. Nat Biotechnol. 2011 Nov 27; 29(12):1132-44. View Abstract
188. Cell cycle adaptations of embryonic stem cells. Proc Natl Acad Sci U S A. 2011 Nov 29; 108(48):19252-7. View Abstract
189. Induced pluripotent stem cells--opportunities for disease modelling and drug discovery. Nat Rev Drug Discov. 2011 Nov 11; 10(12):915-29. View Abstract
190. Lineage regulators direct BMP and Wnt pathways to cell-specific programs during differentiation and regeneration. Cell. 2011 Oct 28; 147(3):577-89. View Abstract
191. Stem cells: Triple genomes go far. Nature. 2011 Oct 05; 478(7367):40-1. View Abstract
192. The Lin28/let-7 axis regulates glucose metabolism. Cell. 2011 Sep 30; 147(1):81-94. View Abstract
193. Midbody accumulation through evasion of autophagy contributes to cellular reprogramming and tumorigenicity. Nat Cell Biol. 2011 Sep 11; 13(10):1214-23. View Abstract
194. Metabolic regulation of protein N-alpha-acetylation by Bcl-xL promotes cell survival. Cell. 2011 Aug 19; 146(4):607-20. View Abstract
195. Induced pluripotent stem cells for modelling human diseases. Philos Trans R Soc Lond B Biol Sci. 2011 Aug 12; 366(1575):2274-85. View Abstract
196. Telomere dynamics in dyskeratosis congenita: the long and the short of iPS. Cell Res. 2011 Aug; 21(8):1157-60. View Abstract
197. Induced pluripotent stem cell models from X-linked adrenoleukodystrophy patients. Ann Neurol. 2011 Sep; 70(3):402-9. View Abstract
198. microRNAs become macro players in somatic cell reprogramming. Genome Med. 2011 Jun 22; 3(6):40. View Abstract
199. The nomenclature system should be sustainable, but also practical. Cell Stem Cell. 2011 Jun 03; 8(6):606-7. View Abstract
200. Genome-wide mapping of 5-hydroxymethylcytosine in embryonic stem cells. Nature. 2011 May 19; 473(7347):394-7. View Abstract
201. Transplantation of adult mouse iPS cell-derived photoreceptor precursors restores retinal structure and function in degenerative mice. PLoS One. 2011 Apr 29; 6(4):e18992. View Abstract
202. Induced pluripotent stem cells for neural tissue engineering. Biomaterials. 2011 Aug; 32(22):5023-32. View Abstract
203. Interactions between Cdx genes and retinoic acid modulate early cardiogenesis. Dev Biol. 2011 Jun 01; 354(1):134-42. View Abstract
204. Investigating monogenic and complex diseases with pluripotent stem cells. Nat Rev Genet. 2011 Apr; 12(4):266-75. View Abstract
205. Somatic coding mutations in human induced pluripotent stem cells. Nature. 2011 Mar 03; 471(7336):63-7. View Abstract
206. Tet1 and Tet2 regulate 5-hydroxymethylcytosine production and cell lineage specification in mouse embryonic stem cells. Cell Stem Cell. 2011 Feb 04; 8(2):200-13. View Abstract
207. Stage-specific signaling through TGFß family members and WNT regulates patterning and pancreatic specification of human pluripotent stem cells. Development. 2011 Mar; 138(5):861-71. View Abstract
208. Cellular therapy for fanconi anemia: the past, present, and future. Biol Blood Marrow Transplant. 2011 Jan; 17(1 Suppl):S109-14. View Abstract
209. Genomic approaches to deconstruct pluripotency. Annu Rev Genomics Hum Genet. 2011; 12:165-85. View Abstract
210. Induced pluripotent stem cells: a novel frontier in the study of human primary immunodeficiencies. J Allergy Clin Immunol. 2011 Jun; 127(6):1400-7.e4. View Abstract
211. Another horse in the meta-stable state of pluripotency. Cell Stem Cell. 2010 Dec 03; 7(6):641-2. View Abstract
212. MicroRNA profiling reveals two distinct p53-related human pluripotent stem cell states. Cell Stem Cell. 2010 Dec 03; 7(6):671-81. View Abstract
213. From Hen House to Bedside: Tracing Hanafusa's Legacy from Avian Leukemia Viruses to SRC to ABL and Beyond. Genes Cancer. 2010 Dec; 1(12):1164-9. View Abstract
214. Large intergenic non-coding RNA-RoR modulates reprogramming of human induced pluripotent stem cells. Nat Genet. 2010 Dec; 42(12):1113-7. View Abstract
215. Hematopoietic differentiation of induced pluripotent stem cells from patients with mucopolysaccharidosis type I (Hurler syndrome). Blood. 2011 Jan 20; 117(3):839-47. View Abstract
216. Highly efficient reprogramming to pluripotency and directed differentiation of human cells with synthetic modified mRNA. Cell Stem Cell. 2010 Nov 05; 7(5):618-30. View Abstract
217. Dynamic instability of genomic methylation patterns in pluripotent stem cells. Epigenetics Chromatin. 2010 Sep 24; 3(1):17. View Abstract
218. Epigenetic memory in induced pluripotent stem cells. Nature. 2010 Sep 16; 467(7313):285-90. View Abstract
219. Comprehensive methylome map of lineage commitment from haematopoietic progenitors. Nature. 2010 Sep 16; 467(7313):338-42. View Abstract
220. Clump passaging and expansion of human embryonic and induced pluripotent stem cells on mouse embryonic fibroblast feeder cells. Curr Protoc Stem Cell Biol. 2010 Aug; Chapter 1:Unit 1C.10. View Abstract
221. All-trans retinoic acid directs urothelial specification of murine embryonic stem cells via GATA4/6 signaling mechanisms. PLoS One. 2010 Jul 13; 5(7):e11513. View Abstract
222. Molecular basis of the first cell fate determination in mouse embryogenesis. Cell Res. 2010 Sep; 20(9):982-93. View Abstract
223. Musashi-2 regulates normal hematopoiesis and promotes aggressive myeloid leukemia. Nat Med. 2010 Aug; 16(8):903-8. View Abstract
224. Reprogramming of T cells from human peripheral blood. Cell Stem Cell. 2010 Jul 02; 7(1):15-9. View Abstract
225. Straight talk with...George Daley. Interview by Elie Dolgin. Nat Med. 2010 Jun; 16(6):624. View Abstract
226. Robust enhancement of neural differentiation from human ES and iPS cells regardless of their innate difference in differentiation propensity. Stem Cell Rev Rep. 2010 Jun; 6(2):270-81. View Abstract
227. Lin28a transgenic mice manifest size and puberty phenotypes identified in human genetic association studies. Nat Genet. 2010 Jul; 42(7):626-30. View Abstract
228. Cdx4 is dispensable for murine adult hematopoietic stem cells but promotes MLL-AF9-mediated leukemogenesis. Haematologica. 2010 Oct; 95(10):1642-50. View Abstract
229. Differential modeling of fragile X syndrome by human embryonic stem cells and induced pluripotent stem cells. Cell Stem Cell. 2010 May 07; 6(5):407-11. View Abstract
230. Interaction of retinoic acid and scl controls primitive blood development. Blood. 2010 Jul 15; 116(2):201-9. View Abstract
231. AID for reprogramming. Cell Res. 2010 Mar; 20(3):253-5. View Abstract
232. Lin28: A microRNA regulator with a macro role. Cell. 2010 Feb 19; 140(4):445-9. View Abstract
233. Telomere elongation in induced pluripotent stem cells from dyskeratosis congenita patients. Nature. 2010 Mar 11; 464(7286):292-6. View Abstract
234. Knockdown of Fanconi anemia genes in human embryonic stem cells reveals early developmental defects in the hematopoietic lineage. Blood. 2010 Apr 29; 115(17):3453-62. View Abstract
235. Targeting Bcr-Abl by combining allosteric with ATP-binding-site inhibitors. Nature. 2010 Jan 28; 463(7280):501-6. View Abstract
236. Stem cells: roadmap to the clinic. J Clin Invest. 2010 Jan; 120(1):8-10. View Abstract
237. Generation of functional human hepatic endoderm from human induced pluripotent stem cells. Hepatology. 2010 Jan; 51(1):329-35. View Abstract
238. AP24163 inhibits the gatekeeper mutant of BCR-ABL and suppresses in vitro resistance. Chem Biol Drug Des. 2010 Feb; 75(2):223-7. View Abstract
239. A robust approach to identifying tissue-specific gene expression regulatory variants using personalized human induced pluripotent stem cells. PLoS Genet. 2009 Nov; 5(11):e1000718. View Abstract
240. Autologous blood cell therapies from pluripotent stem cells. Blood Rev. 2010 Jan; 24(1):27-37. View Abstract
241. Differential methylation of tissue- and cancer-specific CpG island shores distinguishes human induced pluripotent stem cells, embryonic stem cells and fibroblasts. Nat Genet. 2009 Dec; 41(12):1350-3. View Abstract
242. Live cell imaging distinguishes bona fide human iPS cells from partially reprogrammed cells. Nat Biotechnol. 2009 Nov; 27(11):1033-7. View Abstract
243. Disease models from pluripotent stem cells. Ann N Y Acad Sci. 2009 Sep; 1176:191-6. View Abstract
244. Hematopoietic development from human induced pluripotent stem cells. Ann N Y Acad Sci. 2009 Sep; 1176:219-27. View Abstract
245. 9-(Arenethenyl)purines as dual Src/Abl kinase inhibitors targeting the inactive conformation: design, synthesis, and biological evaluation. J Med Chem. 2009 Aug 13; 52(15):4743-56. View Abstract
246. A role for Lin28 in primordial germ-cell development and germ-cell malignancy. Nature. 2009 Aug 13; 460(7257):909-13. View Abstract
247. microRNA expression during trophectoderm specification. PLoS One. 2009 Jul 03; 4(7):e6143. View Abstract
248. Balancing work and life: a conversation with George Daley. Interviewed by Majlinda Lako and Susan Daher. Stem Cells. 2009 Jul; 27(7):1469-70. View Abstract
249. Cross-regulation of the Nanog and Cdx2 promoters. Cell Res. 2009 Sep; 19(9):1052-61. View Abstract
250. Gene targeting of a disease-related gene in human induced pluripotent stem and embryonic stem cells. Cell Stem Cell. 2009 Jul 02; 5(1):97-110. View Abstract
251. Bone-marrow adipocytes as negative regulators of the haematopoietic microenvironment. Nature. 2009 Jul 09; 460(7252):259-63. View Abstract
252. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009 Jul; 41(7):843-8. View Abstract
253. Down's syndrome suppression of tumour growth and the role of the calcineurin inhibitor DSCR1. Nature. 2009 Jun 25; 459(7250):1126-30. View Abstract
254. Biomechanical forces promote embryonic haematopoiesis. Nature. 2009 Jun 25; 459(7250):1131-5. View Abstract
255. Surface antigen phenotypes of hematopoietic stem cells from embryos and murine embryonic stem cells. Blood. 2009 Jul 09; 114(2):268-78. View Abstract
256. Functional evidence that the self-renewal gene NANOG regulates human tumor development. Stem Cells. 2009 May; 27(5):993-1005. View Abstract
257. Upping the ante: recent advances in direct reprogramming. Mol Ther. 2009 Jun; 17(6):947-53. View Abstract
258. Targeted and genome-scale strategies reveal gene-body methylation signatures in human cells. Nat Biotechnol. 2009 Apr; 27(4):361-8. View Abstract
259. Targeted bisulfite sequencing reveals changes in DNA methylation associated with nuclear reprogramming. Nat Biotechnol. 2009 Apr; 27(4):353-60. View Abstract
260. Genetic interaction of PGE2 and Wnt signaling regulates developmental specification of stem cells and regeneration. Cell. 2009 Mar 20; 136(6):1136-47. View Abstract
261. Generation of induced pluripotent stem cells from human blood. Blood. 2009 May 28; 113(22):5476-9. View Abstract
262. Broader implications of defining standards for the pluripotency of iPSCs. Cell Stem Cell. 2009 Mar 06; 4(3):200-1; author reply 202. View Abstract
263. ICSBP-mediated immune protection against BCR-ABL-induced leukemia requires the CCL6 and CCL9 chemokines. Blood. 2009 Apr 16; 113(16):3813-20. View Abstract
264. Common themes of dedifferentiation in somatic cell reprogramming and cancer. Cold Spring Harb Symp Quant Biol. 2008; 73:171-4. View Abstract
265. Human iPS cell derivation/reprogramming. Curr Protoc Stem Cell Biol. 2009 Jan; Chapter 4:Unit 4A.1. View Abstract
266. Efficient gene knockdowns in human embryonic stem cells using lentiviral-based RNAi. Methods Mol Biol. 2009; 482:35-42. View Abstract
267. Application of induced pluripotent stem cells to hematologic disease. Cytotherapy. 2009; 11(8):980-9. View Abstract
268. New ISSCR guidelines underscore major principles for responsible translational stem cell research. Cell Stem Cell. 2008 Dec 04; 3(6):607-9. View Abstract
269. BCR-ABL1-positive CML and BCR-ABL1-negative chronic myeloproliferative disorders: some common and contrasting features. Leukemia. 2008 Nov; 22(11):1975-89. View Abstract
270. From fibroblasts to iPS cells: induced pluripotency by defined factors. J Cell Biochem. 2008 Nov 01; 105(4):949-55. View Abstract
271. Mesodermal patterning activity of SCL. Exp Hematol. 2008 Dec; 36(12):1593-603. View Abstract
272. Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol. 2008 Oct; 15(10):1109-18. View Abstract
273. Disease-specific induced pluripotent stem cells. Cell. 2008 Sep 05; 134(5):877-86. View Abstract
274. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem. 2008 Aug 01; 283(31):21310-4. View Abstract
275. Ras-MAPK signaling promotes trophectoderm formation from embryonic stem cells and mouse embryos. Nat Genet. 2008 Jul; 40(7):921-6. View Abstract
276. Cdx gene deficiency compromises embryonic hematopoiesis in the mouse. Proc Natl Acad Sci U S A. 2008 Jun 03; 105(22):7756-61. View Abstract
277. Molecular basis of pluripotency. Hum Mol Genet. 2008 Apr 15; 17(R1):R23-7. View Abstract
278. Mitotic spindle destabilization and genomic instability in Shwachman-Diamond syndrome. J Clin Invest. 2008 Apr; 118(4):1511-8. View Abstract
279. Enhanced plating efficiency of trypsin-adapted human embryonic stem cells is reversible and independent of trisomy 12/17. Cloning Stem Cells. 2008 Mar; 10(1):107-18. View Abstract
280. Prospects for stem cell-based therapy. Cell. 2008 Feb 22; 132(4):544-8. View Abstract
281. Selective blockade of microRNA processing by Lin28. Science. 2008 Apr 04; 320(5872):97-100. View Abstract
282. Modulation of murine embryonic stem cell-derived CD41+c-kit+ hematopoietic progenitors by ectopic expression of Cdx genes. Blood. 2008 May 15; 111(10):4944-53. View Abstract
283. Isolation of hematopoietic stem cells from mouse embryonic stem cells. Curr Protoc Stem Cell Biol. 2008 Feb; Chapter 1:Unit 1F.3. View Abstract
284. Human embryonic stem cell derivation from poor-quality embryos. Nat Biotechnol. 2008 Feb; 26(2):212-4. View Abstract
285. BMP and Wnt specify hematopoietic fate by activation of the Cdx-Hox pathway. Cell Stem Cell. 2008 Jan 10; 2(1):72-82. View Abstract
286. Derivation and maintenance of human embryonic stem cells from poor-quality in vitro fertilization embryos. Nat Protoc. 2008; 3(5):923-33. View Abstract
287. Generation of human-induced pluripotent stem cells. Nat Protoc. 2008; 3(7):1180-6. View Abstract
288. Reprogramming of human somatic cells to pluripotency with defined factors. Nature. 2008 Jan 10; 451(7175):141-6. View Abstract
289. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007 Sep 15; 110(6):1295-302. View Abstract
290. Current prospects for the generation of patient-specific pluripotent cells from adult tissues. Regen Med. 2007 Sep; 2(5):743-52. View Abstract
291. Teratoma formation assays with human embryonic stem cells: a rationale for one type of human-animal chimera. Cell Stem Cell. 2007 Sep 13; 1(3):253-8. View Abstract
292. Quantitative monitoring by polymerase colony assay of known mutations resistant to ABL kinase inhibitors. Oncogene. 2008 Jan 31; 27(6):775-82. View Abstract
293. Recombination signatures distinguish embryonic stem cells derived by parthenogenesis and somatic cell nuclear transfer. Cell Stem Cell. 2007 Sep 13; 1(3):346-52. View Abstract
294. Debugging cellular reprogramming. Nat Cell Biol. 2007 Aug; 9(8):871-3. View Abstract
295. Hemogenic endothelial progenitor cells isolated from human umbilical cord blood. Stem Cells. 2007 Nov; 25(11):2770-6. View Abstract
296. Towards hematopoietic reconstitution from embryonic stem cells: a sanguine future. Curr Opin Hematol. 2007 Jul; 14(4):343-7. View Abstract
297. Human embryonic stem cells flock together. Nat Biotechnol. 2007 Jul; 25(7):748-50. View Abstract
298. Prostaglandin E2 regulates vertebrate haematopoietic stem cell homeostasis. Nature. 2007 Jun 21; 447(7147):1007-11. View Abstract
299. Farnesyl transferase inhibitor resistance probed by target mutagenesis. Blood. 2007 Sep 15; 110(6):2102-9. View Abstract
300. Gametes from embryonic stem cells: a cup half empty or half full? Science. 2007 Apr 20; 316(5823):409-10. View Abstract
301. The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood. 2007 Jul 01; 110(1):171-9. View Abstract
302. Differentiation potential of histocompatible parthenogenetic embryonic stem cells. Ann N Y Acad Sci. 2007 Jun; 1106:209-18. View Abstract
303. Derivation of hematopoietic stem cells from murine embryonic stem cells. J Vis Exp. 2007 Feb 25; (2):162. View Abstract
304. The cdx-hox pathway in hematopoietic stem cell formation from embryonic stem cells. Ann N Y Acad Sci. 2007 Jun; 1106:197-208. View Abstract
305. Ethics. The ISSCR guidelines for human embryonic stem cell research. Science. 2007 Feb 02; 315(5812):603-4. View Abstract
306. Towards the generation of patient-specific pluripotent stem cells for combined gene and cell therapy of hematologic disorders. Hematology Am Soc Hematol Educ Program. 2007; 17-22. View Abstract
307. Histocompatible embryonic stem cells by parthenogenesis. Science. 2007 Jan 26; 315(5811):482-6. View Abstract
308. Cdx4 dysregulates Hox gene expression and generates acute myeloid leukemia alone and in cooperation with Meis1a in a murine model. Proc Natl Acad Sci U S A. 2006 Nov 07; 103(45):16924-9. View Abstract
309. Progress and prospects: gene transfer into embryonic stem cells. Gene Ther. 2006 Oct; 13(20):1431-9. View Abstract
310. Activity of dual SRC-ABL inhibitors highlights the role of BCR/ABL kinase dynamics in drug resistance. Proc Natl Acad Sci U S A. 2006 Jun 13; 103(24):9244-9. View Abstract
311. Stem cells and their niche: a matter of fate. Cell Mol Life Sci. 2006 Apr; 63(7-8):760-6. View Abstract
312. Pilot study of lonafarnib, a farnesyl transferase inhibitor, in patients with chronic myeloid leukemia in the chronic or accelerated phase that is resistant or refractory to imatinib therapy. Cancer. 2006 Jan 15; 106(2):346-52. View Abstract
313. Acceleration of mesoderm development and expansion of hematopoietic progenitors in differentiating ES cells by the mouse Mix-like homeodomain transcription factor. Blood. 2006 Apr 15; 107(8):3122-30. View Abstract
314. Male germ cells. Methods Enzymol. 2006; 418:307-14. View Abstract
315. Transgene expression and RNA interference in embryonic stem cells. Methods Enzymol. 2006; 420:49-64. View Abstract
316. Anticipating clinical resistance to target-directed agents : the BCR-ABL paradigm. Mol Diagn Ther. 2006; 10(2):67-76. View Abstract
317. In vitro generation of germ cells from murine embryonic stem cells. Nat Protoc. 2006; 1(4):2026-36. View Abstract
318. Novel role for PDEF in epithelial cell migration and invasion. Cancer Res. 2005 Dec 15; 65(24):11572-80. View Abstract
319. Embryonic stem cell-derived hematopoietic stem cells. Proc Natl Acad Sci U S A. 2005 Dec 27; 102(52):19081-6. View Abstract
320. Scientific and clinical opportunities for modeling blood disorders with embryonic stem cells. Blood. 2006 Apr 01; 107(7):2605-12. View Abstract
321. Therapeutic potential of embryonic stem cells. Blood Rev. 2005 Nov; 19(6):321-31. View Abstract
322. Patterning definitive hematopoietic stem cells from embryonic stem cells. Exp Hematol. 2005 Sep; 33(9):971-9. View Abstract
323. Customized human embryonic stem cells. Nat Biotechnol. 2005 Jul; 23(7):826-8. View Abstract
324. Chronic myeloid leukaemia: an investigation into the role of Bcr-Abl-induced abnormalities in glucose transport regulation. Oncogene. 2005 May 05; 24(20):3257-67. View Abstract
325. High-efficiency RNA interference in human embryonic stem cells. Stem Cells. 2005 Mar; 23(3):299-305. View Abstract
326. The homeobox gene HEX regulates proliferation and differentiation of hemangioblasts and endothelial cells during ES cell differentiation. Blood. 2005 Jun 15; 105(12):4590-7. View Abstract
327. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb; 7(2):129-41. View Abstract
328. Stem cell research: science, ethics and policy. Med Ethics (Burlingt Mass). 2005; 12(1):5. View Abstract
329. Inducible transgene expression in mouse stem cells. Methods Mol Med. 2005; 105:23-46. View Abstract
330. Altered nuclear transfer in stem-cell research - a flawed proposal. N Engl J Med. 2004 Dec 30; 351(27):2791-2. View Abstract
331. In vitro gametogenesis from embryonic stem cells. Curr Opin Cell Biol. 2004 Dec; 16(6):688-92. View Abstract
332. Chronic myeloid leukemia: proving ground for cancer stem cells. Cell. 2004 Oct 29; 119(3):314-6. View Abstract
333. Bayesian analysis of signaling networks governing embryonic stem cell fate decisions. Bioinformatics. 2005 Mar; 21(6):741-53. View Abstract
334. Missed opportunities in embryonic stem-cell research. N Engl J Med. 2004 Aug 12; 351(7):627-8. View Abstract
335. Alchemy in the liver: fact or fusion? Nat Med. 2004 Jul; 10(7):671-2. View Abstract
336. A cytoskeleton-based functional genetic screen identifies Bcl-xL as an enhancer of metastasis, but not primary tumor growth. Oncogene. 2004 Jun 03; 23(26):4641-5. View Abstract
337. Taking stock and planning for the next decade: realistic prospects for stem cell therapies for the nervous system. J Neurosci Res. 2004 Apr 15; 76(2):157-68. View Abstract
338. Multivariate proteomic analysis of murine embryonic stem cell self-renewal versus differentiation signaling. Proc Natl Acad Sci U S A. 2004 Mar 02; 101(9):2900-5. View Abstract
339. Genetic complementation of cytokine signaling identifies central role of kinases in hematopoietic cell proliferation. Oncogene. 2004 Feb 12; 23(6):1214-20. View Abstract
340. Mechanisms and implications of imatinib resistance mutations in BCR-ABL. Curr Opin Hematol. 2004 Jan; 11(1):35-43. View Abstract
341. Origins of mammalian hematopoiesis: in vivo paradigms and in vitro models. Curr Top Dev Biol. 2004; 60:127-96. View Abstract
342. Nuclear transplantation, embryonic stem cells and the potential for cell therapy. Hematol J. 2004; 5 Suppl 3:S114-7. View Abstract
343. LIF/STAT3 signaling fails to maintain self-renewal of human embryonic stem cells. Stem Cells. 2004; 22(5):770-8. View Abstract
344. Derivation of embryonic germ cells and male gametes from embryonic stem cells. Nature. 2004 Jan 08; 427(6970):148-54. View Abstract
345. Treatment by design in leukemia, a meeting report, Philadelphia, Pennsylvania, December 2002. Leukemia. 2003 Dec; 17(12):2358-82. View Abstract
346. Hematopoiesis from embryonic stem cells: lessons from and for ontogeny. Exp Hematol. 2003 Nov; 31(11):994-1006. View Abstract
347. A screen to identify drug resistant variants to target-directed anti-cancer agents. Biol Proced Online. 2003; 5:204-210. View Abstract
348. cdx4 mutants fail to specify blood progenitors and can be rescued by multiple hox genes. Nature. 2003 Sep 18; 425(6955):300-6. View Abstract
349. Enhanced hematopoietic differentiation of embryonic stem cells conditionally expressing Stat5. Proc Natl Acad Sci U S A. 2003 Sep 30; 100 Suppl 1:11904-10. View Abstract
350. Cloning and stem cells--handicapping the political and scientific debates. N Engl J Med. 2003 Jul 17; 349(3):211-2. View Abstract
351. ES cells prove egg-straordinary. Nat Biotechnol. 2003 Jul; 21(7):760-1. View Abstract
352. Gleevec resistance: lessons for target-directed drug development. Cell Cycle. 2003 May-Jun; 2(3):190-1. View Abstract
353. From embryos to embryoid bodies: generating blood from embryonic stem cells. Ann N Y Acad Sci. 2003 May; 996:122-31. View Abstract
354. Towards combination target-directed chemotherapy for chronic myeloid leukemia: role of farnesyl transferase inhibitors. Semin Hematol. 2003 Apr; 40(2 Suppl 2):11-4. View Abstract
355. Mechanisms of autoinhibition and STI-571/imatinib resistance revealed by mutagenesis of BCR-ABL. Cell. 2003 Mar 21; 112(6):831-43. View Abstract
356. Dodging the magic bullet: understanding imatinib resistance. Cancer Biol Ther. 2003 Jan-Feb; 2(1):109-10. View Abstract
357. A role for thrombopoietin in hemangioblast development. Stem Cells. 2003; 21(3):272-80. View Abstract
358. Realistic prospects for stem cell therapeutics. Hematology Am Soc Hematol Educ Program. 2003; 398-418. View Abstract
359. Development of hematopoietic repopulating cells from embryonic stem cells. Methods Enzymol. 2003; 365:114-29. View Abstract
360. Novel retroviral vectors to facilitate expression screens in mammalian cells. Nucleic Acids Res. 2002 Dec 15; 30(24):e142. View Abstract
361. Prospects for stem cell therapeutics: myths and medicines. Curr Opin Genet Dev. 2002 Oct; 12(5):607-13. View Abstract
362. Overcoming STI571 resistance with the farnesyl transferase inhibitor SCH66336. Blood. 2002 Aug 01; 100(3):1068-71. View Abstract
363. Efficiency of embryoid body formation and hematopoietic development from embryonic stem cells in different culture systems. Biotechnol Bioeng. 2002 May 20; 78(4):442-53. View Abstract
364. Correction of a genetic defect by nuclear transplantation and combined cell and gene therapy. Cell. 2002 Apr 05; 109(1):17-27. View Abstract
365. HoxB4 confers definitive lymphoid-myeloid engraftment potential on embryonic stem cell and yolk sac hematopoietic progenitors. Cell. 2002 Apr 05; 109(1):29-37. View Abstract
366. A senescence rescue screen identifies BCL6 as an inhibitor of anti-proliferative p19(ARF)-p53 signaling. Genes Dev. 2002 Mar 15; 16(6):681-6. View Abstract
367. A functional screen identifies hDRIL1 as an oncogene that rescues RAS-induced senescence. Nat Cell Biol. 2002 Feb; 4(2):148-53. View Abstract
368. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res. 2002 Jan 15; 62(2):535-41. View Abstract
369. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation. 2001 Nov 27; 104(22):2641-4. View Abstract
370. Clonal analysis of differentiating embryonic stem cells reveals a hematopoietic progenitor with primitive erythroid and adult lymphoid-myeloid potential. Development. 2001 Nov; 128(22):4597-604. View Abstract
371. Cooperative and redundant effects of STAT5 and Ras signaling in BCR/ABL transformed hematopoietic cells. Oncogene. 2001 Sep 13; 20(41):5826-35. View Abstract
372. Expression of interferon consensus sequence binding protein induces potent immunity against BCR/ABL-induced leukemia. Blood. 2001 Jun 01; 97(11):3491-7. View Abstract
373. Autocrine and paracrine effects of an ES-cell derived, BCR/ABL-transformed hematopoietic cell line that induces leukemia in mice. Oncogene. 2001 May 10; 20(21):2636-46. View Abstract
374. Treatment of Bcr/Abl-positive acute lymphoblastic leukemia in P190 transgenic mice with the farnesyl transferase inhibitor SCH66336. Blood. 2001 Mar 01; 97(5):1399-403. View Abstract
375. Activity of the farnesyl protein transferase inhibitor SCH66336 against BCR/ABL-induced murine leukemia and primary cells from patients with chronic myeloid leukemia. Blood. 2001 Mar 01; 97(5):1404-12. View Abstract
376. The heart SNPs a beat: polymorphisms in candidate genes for cardiovascular disease. Trends Cardiovasc Med. 2001 Feb; 11(2):60-6. View Abstract
377. Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet. 2000 Nov; 26(3):291-9. View Abstract
378. Leukemia inhibitory factor (LIF) concentration modulates embryonic stem cell self-renewal and differentiation independently of proliferation. Biotechnol Bioeng. 2000 Sep 20; 69(6):607-17. View Abstract
379. A genetic screen to identify genes that rescue the slow growth phenotype of c-myc null fibroblasts. Oncogene. 2000 Jul 06; 19(29):3330-4. View Abstract
380. Mining for SNPs: putting the common variants--common disease hypothesis to the test. Pharmacogenomics. 2000 Feb; 1(1):27-37. View Abstract
381. The BCR/ABL oncogene alters the chemotactic response to stromal-derived factor-1alpha. Blood. 1999 Dec 15; 94(12):4233-46. View Abstract
382. BCR-ABL and v-SRC tyrosine kinase oncoproteins support normal erythroid development in erythropoietin receptor-deficient progenitor cells. Proc Natl Acad Sci U S A. 1999 Nov 09; 96(23):13186-90. View Abstract
383. Growth factor independence and BCR/ABL transformation: promise and pitfalls of murine model systems and assays. Leukemia. 1999 Aug; 13(8):1200-6. View Abstract
384. Characterization of single-nucleotide polymorphisms in coding regions of human genes. Nat Genet. 1999 Jul; 22(3):231-8. View Abstract
385. The P190, P210, and P230 forms of the BCR/ABL oncogene induce a similar chronic myeloid leukemia-like syndrome in mice but have different lymphoid leukemogenic activity. J Exp Med. 1999 May 03; 189(9):1399-412. View Abstract
386. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Eur Urol. 1999; 35(5-6):355-61. View Abstract
387. Control of hematopoietic differentiation: lack of specificity in signaling by cytokine receptors. Proc Natl Acad Sci U S A. 1998 Jun 09; 95(12):6573-5. View Abstract
388. Secondary mutation maintains the transformed state in BaF3 cells with inducible BCR/ABL expression. Blood. 1998 May 15; 91(10):3927-34. View Abstract
389. Hematopoietic remodeling in interferon-gamma-deficient mice infected with mycobacteria. Blood. 1998 Apr 15; 91(8):2914-24. View Abstract
390. A novel method to isolate cells with conditional gene expression using fluorescence activated cell sorting. Nucleic Acids Res. 1997 Dec 01; 25(23):4858-60. View Abstract
391. Rationalizing autotransplant strategies for chronic myeloid leukemia. Leuk Lymphoma. 1996 May; 21(5-6):353-8. View Abstract
392. Genetic events in CML: from translocation to transplantation. Bone Marrow Transplant. 1994; 14 Suppl 3:S5-9. View Abstract
393. Autologous transplant for CML revisited. Exp Hematol. 1993 Jun; 21(6):734-7. View Abstract
394. Animal models of BCR/ABL-induced leukemias. Leuk Lymphoma. 1993; 11 Suppl 1:57-60. View Abstract
395. Nonmyristoylated Abl proteins transform a factor-dependent hematopoietic cell line. Mol Cell Biol. 1992 Apr; 12(4):1864-71. View Abstract
396. Blast crisis in a murine model of chronic myelogenous leukemia. Proc Natl Acad Sci U S A. 1991 Dec 15; 88(24):11335-8. View Abstract
397. v-abl causes hematopoietic disease distinct from that caused by bcr-abl. Proc Natl Acad Sci U S A. 1991 Aug 01; 88(15):6506-10. View Abstract
398. Activation of phosphatidylinositol 3-kinase in cells expressing abl oncogene variants. Mol Cell Biol. 1991 Feb; 11(2):1107-13. View Abstract
399. Implicating the bcr/abl gene in the pathogenesis of Philadelphia chromosome-positive human leukemia. Adv Cancer Res. 1991; 57:151-84. View Abstract
400. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990 Feb 16; 247(4944):824-30. View Abstract
401. Inhibition of P210BCR/ABL Expression in K562 Cells by Electroporation with an Antisense Oligonucleotide. Leuk Lymphoma. 1990; 3(3):201-8. View Abstract
402. Transformation of an interleukin 3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific P210bcr/abl protein. Proc Natl Acad Sci U S A. 1988 Dec; 85(23):9312-6. View Abstract
403. The CML-specific P210 bcr/abl protein, unlike v-abl, does not transform NIH/3T3 fibroblasts. Science. 1987 Jul 31; 237(4814):532-5. View Abstract
404. Overlapping cDNA clones define the complete coding region for the P210c-abl gene product associated with chronic myelogenous leukemia cells containing the Philadelphia chromosome. Proc Natl Acad Sci U S A. 1986 Dec; 83(24):9768-72. View Abstract
405. The chronic myelogenous leukemia-specific P210 protein is the product of the bcr/abl hybrid gene. Science. 1986 Jul 11; 233(4760):212-4. View Abstract
406. Alternative 5' exons in c-abl mRNA. Cell. 1986 Feb 28; 44(4):577-86. View Abstract
407. Isolation of chicken cellular DNA sequences with homology to the region of viral oncogenes that encodes the tyrosine kinase domain. Mol Cell Biol. 1986 Jan; 6(1):325-31. View Abstract
408. Cellular and molecular aspects of amoeboid movement. Cold Spring Harb Symp Quant Biol. 1982; 46 Pt 1:101-11. View Abstract
Show All Publications Show Fewer Publications